Pleural effusions due to dasatinib

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 4, 2010, Pages 351-356

  Brixey, Anupama G ^a   Light, Richard W ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Chronic myeloid leukaemia; Dasatinib; Pleural effusions

Indexed keywords

DASATINIB; DIURETIC AGENT; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISONE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG WITHDRAWAL; HUMAN; IMMUNE MEDIATED INJURY; INCIDENCE; PATHOGENESIS; PLEURA EFFUSION; PLEURA FLUID; REVIEW; RISK FACTOR; THORACOCENTESIS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PLEURAL EFFUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

CLINICAL TRIALS AS TOPIC; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PLEURAL EFFUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RISK FACTORS; THIAZOLES;

EID: 77953651361     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328338c486     Document Type: Review

References (27)

1. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-2541. (Pubitemid 43882349)
2. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN-107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65:4500-4505.
3. Tokarski JS, Newitt JA, Chang CY, et al. The structure of dasatinib (BMS- 354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66:5790-5797.
4. Kantarjian HM, Talpaz M, Giles F, et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006; 145:913-923. (Pubitemid 351639967)
5. Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007; 176:814-818.
6. Morelock SY, Sahn SA. Drugs and the pleura. Chest 1999; 116:212-221.
7. Huggins JT, Sahn SA. Drug-induced pleural disease. Clin Chest Med 2004; 25:141-153.
8. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25:3908-3914.
9. National Cancer Institute. Common Terminology Criteria for Adverse Events, version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic- applica tions/docs/ctcaev3.pdf.
10. Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol 2009; 27:3472-3479.
11. Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140mg once daily versus 70mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15 month median followup. Blood 2009; 113:6322-6329.
12. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improved tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26:3204-3212.
13. Porkka K, Khoury HJ, Pquette RL, et al. Dasatinib 100mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010; 116:377-386.
14. Dasatinib prescribing information. Princeton, New Jersey: Bristol-Myers Squibb Company. http://packageinserts.bms.com/pi/pi-sprycel.pdf.
15. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete haematological and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109:3207-3213.
16. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood2007; 109:4143-4150. (Pubitemid 46743375)
17. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109:5143-5150. (Pubitemid 46890528)
18. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110:2309-2315.
19. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22:1200-1206.
20. de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008; 141:745-747.
21. Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22:2176-2183.
22. Goldblatt M, Huggins JT, Doelken P, et al. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci 2009; 338:414-417.
23. Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127:330-339.
24. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110:4055-4063.
25. Wang X, Hochhaus A, Kantarjian HM, et al. Dasatinib pharmacokinetics and exposure-response (E-R): relationship to safety and efficacy in patients with chronic myeloid leukemia. J Clin Oncol 2008; 26 (15S):3590.
26. Tyler T. Once daily dasatinib for treatment of patients with chronic myeloid leukemia. Ann Pharmacother 2009; 43:920-927.
27. Light RW, Rogers JT, Cheng D, Rodriguez RM and Cardiovascular Surgery Associates, PC. Large pleural effusions occurring after coronary artery bypass grafting. Ann Intern Med 1999; 130:891-896.